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Soluble suppression of tumorigenicity 2 (sST2) has emerged as a biomarker of cardiac 
stretch or remodeling, and has demonstrated a role in acutely decompensated heart fail-
ure. However, its role in sepsis-induced cardiac dysfunction is still unknown. We explored 
whether sST2 serum concentration reflects either systolic or diastolic dysfunction as mea-
sured by Doppler echocardiography. In a total of 127 patients with sepsis, correlations be-
tween sST2 and blood pressure, left ventricular (LV) ejection fraction, LV diastolic filling 
(ratio of early transmitral flow velocity to early diastolic mitral annulus velocity), and resting 
pulmonary arterial pressure were evaluated. Correlations between sST2 and other sepsis 
biomarkers (high-sensitivity C-reactive protein [hs-CRP] and procalcitonin) were also ex-
amined. sST2 showed a moderate correlation with mean arterial pressure (r=-0.3499) 
but no correlation with LV ejection fraction, diastolic filling, or resting pulmonary hyperten-
sion. It showed moderate correlations with hs-CRP and procalcitonin (r=0.2608 and 
r=0.3829, respectively). sST2 might have a role as a biomarker of shock or inflammation, 
but it cannot reflect echocardiographic findings of LV ejection fraction or diastolic filling in 
sepsis.
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Sepsis is life-threatening organ dysfunction from a dysregulated 
host response to infection [1]. Among sepsis-induced complica-
tions, the development of hemodynamic instability or cardiac 
dysfunction is a major risk factor of in-hospital mortality. For 
early detection of sepsis-induced cardiac dysfunction (SICD), 
immediate echocardiography is crucial but may be delayed ow-
ing to inability of bedside skilled staff or high cost. For early di-
agnosis and decision-making in this critical setting, biomarkers 
like high-sensitivity C-reactive protein (hs-CRP) and procalcito-
nin (PCT) have been suggested to indicate septic processes [2]. 
A multi-marker or complementary approach with other biomark-
ers related to SICD might be helpful to determine the appropri-
ate therapy for cardiovascular support.
Among the emerging cardiac inflammatory biomarkers, solu-
ble suppression of tumorigenicity 2 (sST2), a member of the 
Toll-like/interleukin (IL)-1 receptor superfamily, seems promis-
ing. Clinical studies revealed the diagnostic value of sST2 for 
acute myocardial infarction, acute heart failure, sepsis, and 
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trauma [3-5]. Recently, we demonstrated the prognostic role of 
sST2 in sepsis and its association with the cardiovascular sub-
score of sepsis-related organ failure assessment (SOFA) scores 
[6]. However, the cardiac subset of SOFA elements consist of 
only mean arterial pressure and use of a vasopressor, which are 
too limited to reflect SICD alone [7]. In this study, we hypothe-
sized that SICD would result in enough mechanical stress to re-
lease sST2, and sST2 may reflect systolic or diastolic dysfunc-
tion as measured by Doppler echocardiography in sepsis pa-
tients. We explored whether sST2 correlates with echocardio-
graphic findings and other sepsis biomarkers or not.
A retrospective study was conducted in two tertiary referral 
hospitals: Sant’Andrea Hospital (SAH), Rome, Italy and Konkuk 
University Medical Center (KUMC), Seoul, Korea. The hospital 
echocardiographic database including medical/surgical inten-
sive care units, general wards, and emergency department was 
searched for the period from November 1, 2013 to May 31, 
2014 (SAH) and November 1, 2013 to August 31, 2014 
(KUMC). This study was conducted separately from our previ-
ous study [6] that has the overlapping study period, using a dif-
ferent study protocol. This study protocol involved reviewing 
medical records on clinical, laboratory, and echocardiographic 
data. The protocol met the criteria of the Declaration of Helsinki 
and was approved by the Institutional Review Board of each 
hospital. Informed consent was obtained from each patient in 
SAH for the biomarker measurement and review of medical re-
cords; in KUMC, it was exempted for this retrospective study.
Among the eligible adult patients (≥18 yr) who had available 
echocardiographic data, only the patients diagnosed as having 
sepsis and with relevant laboratory data were included. Al-
though echocardiography is not a routine practice for every sep-
tic patient, the decision to perform echocardiography was made 
by the attending clinicians when the patient had hemodynamic 
instability, dyspnea, and/or abnormal radiographic findings on a 
chest X-ray. Each patient was considered eligible only when it 
was his or her first time in the hospital due to sepsis. Because 
the patients were searched not by the whole hospital database 
but by the echocardiographic database, information on how 
many patients were diagnosed as having sepsis during the 
study period was not available for this study. The following ex-
clusion criteria were applied in the following order: patients’ age 
<18 yr; absence of routine laboratory data for PCT and/or hs-
CRP that were measured concomitantly with echocardiography 
(on the same day or within 24 hr); and absence of concomi-
tantly obtained frozen samples, acute coronary syndrome, and 
documented history of symptomatic heart failure. 
Recently, the diagnosis of sepsis was redefined according to 
the most up-to-date consensus definition [1]. Among the eligible 
136 patients, nine patients were excluded owing to acute coro-
nary syndrome (N=2), documented history of symptomatic 
heart failure (N=4), and the new sepsis definition (N=3) (Sup-
plemental Data Fig. S1). We enrolled 127 patients (110 patients 
from KUMC and 17 patients from SAH), consisting of 95 pa-
tients with sepsis (74.8%) and 32 patients with septic shock 
(25.2%) (Table 1). The median age was 71 yr (range, 58-80 yr), 
and 55% of patients were male. No statistical difference was 
observed between the patients from KUMC and SAH, in terms 
of age, sex, use of vasopressor, mean arterial pressure, left ven-
tricular (LV) ejection fraction (EF), or sST2 concentrations. Their 
underlying medical conditions were: pneumonia (N=47), he-
matologic immunocompromised state (N=19), urinary tract in-
fection (N=15), hepatobiliary (N=14), cerebral (N=12), solid 
organ malignancy (N=8), bone or spine (N=6), gastrointestinal 
(N=5), and others (N=1, mucormycosis).
Serum PCT and hs-CRP concentrations were measured ac-
cording to the manufacturers’ instructions [1]. In KUH, PCT was 
measured by an Elecsys BRAHMS PCT electrochemilumines-
cence assay (BRAHMS, Hennigsdorf, Germany) in a Roche Co-
bas system (Roche Diagnostics, Basel, Switzerland), and in 
SAH PCT was measured by using a BRAHMS PCT sensitive 
Kryptor immunofluorescent assay system (BRAHMS). hs-CRP 
was measured by using the BN II Nephelometer (Dade Behring 
Ins, Newark, DE, USA). Frozen sera stored at -70°C were 
thawed once for sST2 measurement. Briefly, sST2 concentra-
tions were measured in duplicate by using an enzyme-linked 
immunosorbent assay, the Presage ST2 assay (Critical Diagnos-
tics, San Diego, CA, USA) [8]. The maximum total CV (cumula-
tive calculation) of sST2, PCT, and hs-CRP assays in both labo-
ratories were 3%, 3.2%, and 3.3%, respectively.
The transthoracic Doppler echocardiogram records on the Car-
diology PACS system (INFINITT healthcare, Seoul, Korea) were 
reviewed. LV dimensions were measured by M-mode, tracing 
both end-diastolic and end-systolic period. LV systolic function 
was evaluated with EF by two-dimensional images using the 
modified Simpson’s method [9]. LV diastolic function was as-
sessed with the ratio of pulsed-wave Doppler-derived early trans-
mitral inflow velocity (E velocity) and mitral septal annular tissue 
Doppler-derived early diastolic velocity (e’ velocity) (E/e’ ratio) 
[10]. Resting pulmonary arterial systolic pressure (PASP) was as-
sessed via the tricuspid regurgitation jet peak velocity using the 
simplified Bernoulli equation with an assumption of right atrial 
pressure [11]. Two experienced cardiologists reviewed the im-
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ages for apical ballooning, LV outflow dynamic obstruction, or 
right ventricular dysfunction [12]. For discrepant opinions be-
tween them, a consensus was drawn throughout their discussion.
We performed statistical analysis using dBSTAT (DBSTAT Ver-
sion 5. Chuncheon, Korea). Data were expressed as a median 
(interquartile range) for continuous variables and as a number 
(percentage) for categorical variables. We compared clinical, 
laboratory, and echocardiographic data in patients with or with-
out sepsis-induced LV systolic dysfunction (EF <50%). Correla-
tion between sST2 and cardiovascular or inflammatory markers 
was assessed by using Pearson’s correlation coefficient (95% 
confidence interval). Mann-Whitney U test was used for contin-
uous variables, and Fisher’s exact test for categorical variables. 
Obtained P values were not adjusted for multiple comparisons 
and are therefore descriptive only.
Sepsis-induced LV systolic dysfunction was observed in 17 
patients (13.4%) (Table 1). Except for E velocity and PASP, the 
other echocardiographic data showed significant differences 
between the patients with and without LV systolic dysfunction. 
Although median sST2, hs-CRP, and PCT concentrations tended 
Table 1. Comparison between sepsis-induced cardiac dysfunction and normal function
Total 
(N=127)
Systolic dysfunction 
(LV EF <50%) 
(N=17)
Normal function 
(LV EF ≥50%) 
(N=110)
P*
Clinical data
   Age (yr) 71 [58-80] 70 [56-81] 72 [58-80] 0.994
   Sex (male) (N) 70 (55%) 12 (71%) 58 (53%) 0.168
   Heart rate (beats/min) 101 [85-118] 110 [90-132] 101 [84-116] 0.224
   MAP (mmHg) 84.7 [67.3-98.0] 65.3 [51.5-94.5] 85.9 [70.2-98.3] 0.028
   Vasopressor (N) 32 (25%) 9 (53%) 23 (21%) 0.013
Laboratory data
   sST2 (ng/mL) 110.1 [54.2-240.1] 232.0 [50.7-263.5] 103.9 [54.0-237.0] 0.386
   hs-CRP (mg/L) 100.9 [55.3-185.0] 171.7 [83.9-244.6] 99.6 [53.8-165.0] 0.100
   PCT (ng/mL) 0.42 [0.13-3.62] 0.59 [0.11-6.44] 0.39 [0.13-3.35] 0.935
Echocardiographic data
   Apical ballooning (N) 11 (9%) 7 (41%) 4 (4%) <0.0001
   LV EDD (mm) 46.0 [41.0-50.0] 50.0 [47.0-53.5] 45.0 [40.8-50.0] 0.003
   LV ESD (mm) 29.0 [24.0-34.0] 40.0 [36.5-42.5] 28.0 [23.8-32.0] <0.0001
   LV EF (%) 64.4 [56.2-71.0] 42.4 [36.3-47.1] 65.2 [61.3-72.2] <0.0001
   E velocity (m/s) 0.64 [0.52-0.80] 0.62 [0.56-0.71] 0.64 [0.51-0.82] 0.634
   Septal e’ velocity (m/s) 0.06 [0.05-0.08] 0.05 [0.04-0.07] 0.065 [0.05-0.08] 0.021
   Septal E/e’ 9.64 [7.75-12.50] 12.4 [9.1-15.8] 9.2 [7.3-12.2] 0.012
   PASP (mm Hg) 29.4 [24.4-37.0] 31.0 [26.7-34.9] 28.6 [24.4-38.2] 0.562
Data are expressed as number (percentage) or median [interquartile range]. 
*Chi-square test (sex), Fisher’s exact test (vasopressor and apical ballooning), or Mann-Whitney U test was applied to compare two groups.
Abbreviations: MAP, mean arterial pressure; sST2, soluble suppression of tumorigenicity 2; hs-CRP, high-sensitivity C-reactive protein; PCT, procalcitonin; LV, 
left ventricular; EF, ejection fraction; EDD, end-diastolic dimension; ESD, end-systolic dimension; E velocity, early transmural flow velocity; e’ velocity, early di-
astolic mitral annulus velocity; E/e’, ratio of early transmitral flow velocity to early diastolic mitral annulus velocity; PASP, pulmonary arterial systolic pressure.
Table 2. Correlation of sST2 with cardiac functional parameters and 
inflammatory markers
Pearson’s 
correlation 
coefficient (r)
95% 
confidence 
interval
P
sST2 vs Cardiac functional parameters
   MAP (mm Hg) -0.3499 -0.4940--0.1871 <0.0001
   Heart rate (beats/min) 0.2382 0.0668-0.3960 0.007
   LV EF (%) -0.0267 -0.2000-0.1482 0.766
   Septal E/e’ 0.0248 -0.1599-0.2077 0.478
   PASP (mm Hg) -0.0398 -0.2154-0.1382 0.662
sST2 vs Inflammatory markers
   hs-CRP (mg/L) 0.2608 0.0907-0.4161 0.0031
   PCT (ng/dL) 0.3829 0.2156-0.5283 <0.0001
Abbreviations: see Table 1.
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to be higher in the systolic dysfunction group, unadjusted P val-
ues did not indicate a meaningful difference. sST2 concentra-
tion correlated moderately with hs-CRP and PCT concentra-
tions; it also correlated moderately with the hemodynamic pa-
rameters of blood pressure and heart rate. No correlation was 
observed between sST2 concentration and LV EF, septal E/e’, or 
PASP (Table 2).
The heart is one of the most frequently affected organs in 
sepsis; up to 60% of patients with septic shock develop LV EF 
<45% during the first three days [13]. The prevalence or de-
gree of LV dysfunction depends on the timing and severity of 
sepsis. In this study, depressed LV systolic function was ob-
served only in 13.4% of patients, possibly owing to the relatively 
small portion of patients with septic shock (25.2%). In addition, 
the examination timing within 24 hr after blood collection for 
PCT and hs-CRP measurement (approximately the time point 
when the diagnosis of sepsis was established) may include the 
compensatory hyperdynamic contractile period. During early 
phases of sepsis, the LV EF is high (>55%) with insufficient 
cardiac preload due to high vascular permeability and low vas-
cular tone; however, during the later phase with fluid loading, 
EF decreases [14]. Therefore, serial echocardiography Doppler 
monitoring is warranted.
To the best of our knowledge, this is the first study to compare 
sST2 concentration with concomitant Doppler echocardio-
graphic findings in septic patients. We speculated that sepsis-
induced acute LV systolic or diastolic dysfunction, with de-
creased LV EF or elevated LV filling pressure, would be enough 
mechanical stress to release sST2. However, our findings did 
not support this hypothesis, similarly to the recent report that 
revealed no correlation between inflammatory cytokines and 
myocardial dysfunction in septic shock [15]. Sepsis itself may 
trigger sST2 release as an inflammatory mediator, covering up 
any sST2 upregulation from myocardial mechanical strain. The 
median sST2 concentration was 110 [54.2-240.1] ng/mL, and 
most patients (118/127 patients, 92.9%) exhibited higher sST2 
concentrations than the reference value ( ≤35 ng/mL) [8]. 
These results are consistent with our previous study on patients 
with stress cardiomyopathy in a non-cardiac medical intensive 
care unit; initial sST2 concentration did not predict stress car-
diomyopathy, but the 48-hr follow-up sST2 concentration (per-
sistently or newly increased sST2) did [16]. A limitation of our 
study is that we only performed a single sST2 measurement. A 
short-term follow-up of sST2 concentration is necessary to de-
lineate its cardiac-specific role. More specifically, an algorithm 
combining sST2 and echocardiography may be proposed: sST2 
and echocardiography can be evaluated in the early period of 
sepsis (within 24 hr of diagnosis) and followed up after 48 hr of 
the initial evaluation.
Although we excluded the patients with documented history 
of symptomatic heart failure, it is possible that some patients 
had undiagnosed/asymptomatic heart failure or new onset of 
symptomatic failure. This is another limitation of our study. 
Moreover, we could not include other cardiac biomarkers in our 
retrospective analysis. Although cardiac troponins and natri-
uretic peptides have been studied in relation to echocardio-
graphic findings, they did not show satisfactory results [17, 18]. 
Absence of comparison data with the other cardiac biomarkers 
may be another limitation of this study.
It is unclear whether elevated sST2 in acute heart failure is 
produced in cardiac myocytes or elsewhere. Intuitively, sST2 
protein is upregulated by myocardial stress in cultured myo-
cytes [19], but other studies did not show elevated myocardial 
sST2 expression during heart failure [20]. In our sepsis popula-
tion, sST2 is mainly a marker of inflammation, and even in heart 
failure, the major source of circulating sST2 is likely not the 
heart. Therefore, we speculate the possibility of non-myocardial 
or systemic vascular production of sST2 is triggered by altered 
myocardial load or low blood pressure in sepsis (Table 2). 
In conclusion, sST2 might have a role as a biomarker of 
shock or inflammation in sepsis. A single measurement of sST2, 
however, cannot reflect sepsis-induced LV systolic or diastolic 
function evaluated by Doppler echocardiography. Serial mea-
surement of sST2 along with echocardiography Doppler moni-
toring would be necessary to better delineate the role of sST2 as 
a marker of SICD.
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